Cambrian Capital Partners
VC Fund
Cambrian Capital Partners is a firm focused on providing off-market and creative investment solutions.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Cambrian Capital Partners invests in
Stages Cambrian Capital Partners invests in
Countries Cambrian Capital Partners invests in
Investment Focus
Industry
- Fitness 1 (33%)
- Wellness 1 (33%)
- Health Care 1 (33%)
- Life Science 1 (33%)
- Biotechnology 1 (33%)
Stage
- Series A 2 (67%)
- Seed 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Journey Live
|
Journey is a simple meditation practice designed for the modern world, providing on-demand and live-streamed meditation courses.Journey was created to share meditation in a way that all people could relate to, wherever they are in life. It has created a simple yet powerful technique that could appeal to a large-scale audience, changing a lot ofpeople’s lives. It takes a step beyond meditation by introducing six simple yet powerful Life Lessons.Founded in 2015 by Stephen Sokoler, Journey Meditation is headquartered in New York. | $8M / Series A / Jul 25, 2025 | |
CND Life Sciences
|
CND Life Sciences develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy. CND launched the Syn-One Test, a commercially available test to detect, visualize, and quantify the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid inthe confirmation of synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF).CND has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field. | $13.5M / Series A / May 01, 2025 | |
|
CND Life Sciences
|
CND Life Sciences develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy. CND launched the Syn-One Test, a commercially available test to detect, visualize, and quantify the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid inthe confirmation of synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF).CND has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field. | $5M / Seed / Feb 01, 2022 |
Co-Investors
HonorHealth
2 deals together
Canaan Partners
1 deal together
HealthTech Capital
1 deal together
J-Impact
1 deal together
J-Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Cambrian Capital Partners invest in?
Cambrian Capital Partners invests primarily in Fitness, Wellness and Health Care startups, most often at Series A and Seed stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Cambrian Capital Partners last invest?
The most recent investment recorded for Cambrian Capital Partners closed in Jul 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
